Phase 2 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 50 years or older
- People whose best vision (with glasses or contact lenses if needed) falls within a specific range — roughly equivalent to seeing between 20/40 and 20/320 on a standard eye chart — as measured during a screening appointment
- People who have read the information about the study and voluntarily signed a consent form to take part
Who may not be able to join:
- People who have the wet form of age-related macular degeneration (AMD) in both eyes that requires standard treatment (having dry AMD in the non-study eye is permitted)
- People who have previously had treatments such as photodynamic therapy or laser treatment for wet AMD, or who have had surgery related to this condition (note: vitamins and health supplements do not count as treatments here)
- People whose study eye has previously been treated with anti-VEGF injection drugs (such as ranibizumab, bevacizumab, or aflibercept) or combination therapies for wet AMD before the screening visit
- People who have received steroid injections directly into the eye
- People whose study eye has a significant amount of bleeding beneath the retina — specifically, bleeding covering 50% or more of the affected area, or bleeding in the central region of the retina that is larger than a certain size (confirm details with trial site)
- People who have bleeding inside the gel-like fluid of the study eye (known as vitreous hemorrhage)
- People who have previously had surgery to remove the gel inside the eye (vitrectomy)
- People with a history of retinal detachment, a condition present from birth affecting the retina, or any treatment or surgery related to retinal detachment
- People whose study eye has scarring, fibrous tissue, or tissue loss at the very centre of the retina
- People whose study eye has abnormal blood vessel growth caused by something other than wet AMD (though a related condition called polypoidal choroidal vasculopathy is permitted)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kyu Hyeong Park, Seoul National University HospitalSeoul National University Hospital
Phone: 1047070314
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in central retinal thickness (CRT)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.